BUPROPION-SR FOR SMOKING CESSATION IN EARLY RECOVERY FROM ALCOHOL DEPENDENCE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定药物安非他酮-SR在酒精依赖早期康复期间治疗戒烟的有效性。安非他酮-SR是一种已被美国食品和药物管理局(FDA)批准用于戒烟治疗的药物。我们期望这种药物将在酒精依赖早期康复的患者中启动戒烟和保持戒烟的有用。绝大多数接受酒精依赖治疗的患者也吸烟。吸烟与严重的预防性健康风险和过早死亡有关。研究表明，那些接受酒精依赖治疗和戒烟的人，再次酗酒的可能性也较小。符合酒精和尼古丁依赖研究标准的18岁或以上的男性和女性，以及戒酒6周至6个月的人，可能有资格参加。他们必须表明戒烟的愿望，并确定“戒烟日期”。此外，个人必须能够识别我们可以联系的家庭成员或朋友，以询问他们的酒精和烟草使用情况。如果个人有任何癫痫发作障碍、严重头部创伤、脑瘤或中风病史，就不能参加。同样，如果他们服用了任何可能使服用安非他酮-SR变得不可取的药物，他们就不能参与。患有内科或精神疾病，或目前依赖或大量使用其他药物的个人不符合条件。在这项研究期间正在哺乳、怀孕或可能怀孕的妇女也不符合条件。共有80名受试者将从切尔西植物治疗中心招募参加这项研究。我们将按照完成初步评估的顺序接纳有资格参加这项研究的人。通过参加这项研究，你可能会戒烟，因此，你的整体健康可能会得到改善。最重要的是，你可能会提高持续戒酒的机会。您将定期拜访治疗师、精神病学家、执业护士和/或注册护士，以帮助您戒酒和戒烟。大约一半的研究参与者将免费服用安非他酮-SR。研究表明，如果你参加戒烟咨询，你成功戒烟的机会比你自己戒烟的机会更大。那些在接受戒烟咨询的同时还接受积极药物治疗的人在戒烟方面可能会取得更大的成功。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine how effective the medication, bupropion-SR, is for treating smoking cessation during early recovery from alcohol dependence. Bupropion-SR is a medication that has been approved by the United States Food and Drug Administration (FDA) for the treatment of smoking cessation. We expect that this medication will be useful in initiating smoking cessation, and maintaining abstinence from smoking, among patients in early recovery from alcohol dependence. A vast majority of patients treated for alcohol dependence also smoke cigarettes. Cigarette smoking is associated with serious, preventative health risks, and premature death. Studies have shown that those who are treated for alcohol dependence, and who quit smoking, are also less likely to relapse to alcohol use. Men and women, 18 years of age or older, who meet study criteria for alcohol and nicotine dependence, and who have been abstinent from alcohol for 6 weeks to 6 months, may be eligible to participate. They must state a desire to quit smoking and identify a "quit date." In addition, individuals must be able to identify a family member or friend whom we can contact to ask about their alcohol and tobacco use. Individuals cannot participate if they have any history of seizure disorder, severe head trauma, brain tumor, or stroke. Likewise, they cannot participate if they take any medications that may make it inadvisable to take bupropion-SR. Individuals who have a medical or psychiatric illness, or who are currently dependent on, or heavily use other drugs are ineligible. Women who are nursing, pregnant, or likely to become pregnant during this study are also ineligible. A total of 80 subjects will be recruited for this study from Chelsea Arbor Treatment Center. We will admit people who qualify for this study in the order that they complete the initial assessments. By joining this study, you may quit smoking, and, therefore, your overall health may improve. Most importantly, you could possibly improve your chances of sustained sobriety. You will receive regular visits with a therapist, psychiatrist, nurse practitioner, and/or registered nurse to help you with your abstinence from alcohol and cigarettes. Approximately one-half of study participants will be given bupropion-SR, at no cost. Research indicates that you have a greater chance of successfully quitting smoking if you participate in smoking cessation counseling than if you try to quit on your own. Those who are receiving active medication in addition to smoking cessation counseling may have even greater success in quitting.